Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsASX:IDX -2.24%68 EV-to-OCF is 16.61 as of Aug. 07, 2026, which is 0% below its 10-year median of 16.69. GuruFocus rates ASX:IDX with a GF Score™ of 68/100 and a GF Value™ of A$2.80 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 67.61% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Integral Diagnostics's Enterprise Value is A$1,402.6 Mil.
Integral Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$84.4 Mil. Therefore, Integral Diagnostics's EV-to-OCF for today is 16.61.
The historical rank and industry rank for Integral Diagnostics's EV-to-OCF or its related term are showing as below:
ASX:IDX'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.32 Med: 16.69 Max: 25.49
Current: 15.81
During the past 10 years, the highest EV-to-OCF of Integral Diagnostics was 25.49. The lowest was 8.32. And the median was 16.69.
ASX:IDX's EV-to-OCF is ranked worse than 67.61% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.26
vs ASX:IDX: 15.81
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Integral Diagnostics (ASX:IDX) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Integral Diagnostics's PE Ratio (TTM) for today is calculated as:
Integral Diagnostics's share price for today is A$2.18.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.042.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Integral Diagnostics EV-to-OCF Related Terms
Integral Diagnostics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's EV-to-OCF falls into.
Integral Diagnostics's current Enterprise Value is A$1,402.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$84.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a EV-to-OCF of 16.61 as of Aug. 07, 2026. This is near median its historical median of 16.69. Over the past decade, Integral Diagnostics' EV-to-OCF has ranged from 8.32 to 25.49. According to the industry distribution chart, Integral Diagnostics ranks #144 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 67.6%.
Is Integral Diagnostics' EV-to-OCF too high?
Integral Diagnostics' current EV-to-OCF of 16.61 is near median its 10-year median of 16.69. Over the past 10 years, this metric has ranged from a low of 8.32 to a high of 25.49. The Medical Diagnostics & Research industry median EV-to-OCF is 6.26. Integral Diagnostics' value of 16.61 is 165.3% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #144 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #144 out of 213 companies for EV-to-OCF. This places Integral Diagnostics in the lower half of its industry. The industry median EV-to-OCF is 6.26. Integral Diagnostics' value of 16.61 is 165.3% above this benchmark. Historically, Integral Diagnostics' own EV-to-OCF has ranged from 8.32 to 25.49 over the past decade. While the company's 10-year median is 16.69 vs. the industry median of 6.26, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.26, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current EV-to-OCF of 16.61 is 165.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current EV-to-OCF is 16.61, which is near median its own 10-year median of 16.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.80, compared to a current price of A$2.18 — trading 22.1% below its estimated fair value. The current EV-to-OCF is 16.61, which is near median its 10-year median of 16.69 and 165.3% above the Medical Diagnostics & Research industry median of 6.26. Integral Diagnostics' overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current EV-to-OCF is 16.61 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.18 is trading 22.1% below its estimated GF Value™ of A$2.80.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
EV-to-OCF: 16.61 (near median its 10-year median of 16.69)
GF Value™: A$2.80 vs. price of A$2.18 (22.1% below fair value)
Industry Position: 165.3% above the Medical Diagnostics & Research median (#144 of 213)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
68GF Score
Get the complete analysis for ASX:IDX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
